The Chumakov Scientific Center of the Russian Academy of Sciences intends to conduct the third stage of clinical trials of the vaccine against coronavirus infection “KoviVac” in May this year. This was announced on Monday, April 19, by the deputy director general for project activities and innovations of the center, Konstantin Chernov, on the air of the Russia 1 TV channel.
It is specified that more than 32 thousand people will take part in the tests.
“We plan to conduct the third phase of clinical trials of KoviVac starting from May. More than 32 thousand people will be involved there, as we expect, and it will be carried out in relation to risk groups, ”said Chernov.
On April 16, it was reported that the first consignments of the KoviVac vaccine were sent to the regions of Russia.
The first coronavirus vaccine in Russia and in the world was registered on August 11 last year. A drug called “Sputnik V” was developed at the Gamaleya Center. The second Russian vaccine was the drug “EpiVacCorona” from the “Vector” center. It was registered in the fall of 2020.
The third Russian vaccine against coronavirus was developed by the Center. M.P. Chumakov RAS. The drug was named “KoviVak”. The vaccine was registered on February 20.
All relevant information on the situation with the coronavirus is available on the websites of stopcoronavirus.rf and access vsem.rf, as well as by the hashtag #WeVotte. Coronavirus hotline: 8 (800) 2000-112.